Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Cell Death and Differentiation Année : 2022

Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics

Kevin Kinch
Mark Jackson
Gabriel Ichim
Anthony Chalmers

Résumé

Abstract Glioblastoma (GBM) is the most prevalent malignant primary brain tumour in adults. GBM typically has a poor prognosis, mainly due to a lack of effective treatment options leading to tumour persistence or recurrence. We investigated the therapeutic potential of targeting anti-apoptotic BCL-2 proteins in GBM. Levels of anti-apoptotic BCL-xL and MCL-1 were consistently increased in GBM compared with non-malignant cells and tissue. Moreover, we found that relative to their differentiated counterparts, patient-derived GBM stem-like cells also displayed higher expression of anti-apoptotic BCL-2 family members. High anti-apoptotic BCL-xL and MCL-1 expression correlated with heightened susceptibility of GBM to BCL-2 family protein-targeting BH3-mimetics. This is indicative of increased apoptotic priming. Indeed, GBM displayed an obligate requirement for MCL-1 expression in both tumour development and maintenance. Investigating this apoptotic sensitivity, we found that sequential inhibition of BCL-xL and MCL-1 led to robust anti-tumour responses in vivo, in the absence of overt toxicity. These data demonstrate that BCL-xL and MCL-1 pro-survival function is a fundamental prerequisite for GBM survival that can be therapeutically exploited by BH3-mimetics.
Fichier principal
Vignette du fichier
41418_2022_Article_1001.pdf (6.11 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03863787 , version 1 (03-07-2023)

Identifiants

Citer

Anna Koessinger, Catherine Cloix, Dominik Koessinger, Dieter Henrik Heiland, Florian Bock, et al.. Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. Cell Death and Differentiation, 2022, 29 (10), pp.2089-2104. ⟨10.1038/s41418-022-01001-3⟩. ⟨hal-03863787⟩
32 Consultations
14 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More